Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3258527 | 0.98 | GNAI3 (0.47) | GNAI3GNAO1GNAI1EPHX2CA2 | |
| SCHEMBL10403133 | 0.78 | GNAI3 (0.46) | GNAI3GNAO1GNAI1EPHX2CA2 | |
| SCHEMBL3267951 | 0.78 | GNAI3 (0.46) | GNAI3GNAO1GNAI1EPHX2CA2 | |
| SCHEMBL364908 | 0.77 | — | — | |
| SCHEMBL8897925 | 0.76 | GNAI3 (0.44) | GNAI3GNAO1GNAI1EPHX2CA2 | |
| SCHEMBL1459326 | 0.76 | GNAI3 (0.44) | GNAI3GNAO1GNAI1EPHX2CA2 | |
| SCHEMBL1394575 | 0.76 | GNAI3 (0.49) | GNAI3GNAO1GNAI1CA2CA12 | |
| SCHEMBL7430647 | 0.75 | HTT (0.45) | POLB | |
| SCHEMBL2891503 | 0.75 | HTT (0.45) | POLB | |
| SCHEMBL29108006 | 0.74 | GNAI3 (0.47) | GNAI3GNAO1GNAI1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456173-B2 | Compositions comprising zopiclone derivatives and methods of making and using the same | SEPRACOR INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7189715-B2 | Compositions comprising zopiclone derivatives and methods of making and using the same | SEPRACOR INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070049590-A1 | Compositions comprising zopiclone derivatives and methods of making and using the same | ALTER DOMUS (US) LLC | 2007-03-01 | — | — | US | disclosed |
| EP-1089973-B1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040147521-A1 | Compositions comprising zopiclone derivatives and methods of making and using the same | ALTER DOMUS (US) LLC | 2004-07-29 | — | — | US | disclosed |
| WO-2004037212-A2 | COMPOSITIONS COMPRISING ZOPICLONE DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | SEPRACOR, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6335324-B1 | TREATING ASTHMA OR ALLERGIC RHINITIS | BRISTOL-MYERS SQUIBB CO. | 2002-01-01 | — | — | US | disclosed |
| EP-1089973-A4 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1089973-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067215-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049590-A1 | Compositions comprising zopiclone derivatives and methods of making and using the same | CYP51A1, CYP3A43, HSD17B7 | GNAI3 930/4885GNAO1 879/4885GNAI1 1692/4885 |
| US-20040147521-A1 | Compositions comprising zopiclone derivatives and methods of making and using the same | CYP51A1, CYP3A43, CYP4A11 | GNAI3 1161/4885GNAO1 777/4885GNAI1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.